BBOT_KONQUER-101 - Clinical Trial
¿Cuál es el Propósito de este estudio?
Este estudio consta de dos partes. In the first part, researchers will test different doses of the study drug BBO-11818, alone and with other cancer treatments, to find a safe and effective dose. In the second part, more participants with specific types of cancer and KRAS mutations will receive BBO-11818 either by itself or with other medicines. Researchers will study its safety, effectiveness, and side effects.
This study is for people with advanced non-small cell lung cancer, colorectal cancer, pancreatic cancer, or another solid tumor that has a specific KRAS gene mutation. Researchers are testing new treatments for cancers with these KRAS mutations.
¿Quién puede participar en el Estudio?
Participants may be able to join if they are adults with advanced cancer that cannot be removed with surgery or has spread to other parts of the body. They must have measurable tumors, be expected to live at least 12 more weeks, and be willing to complete study visits and procedures. Those with tumors that cannot be treated with curative radiation therapy may also be eligible.
¿Qué Implica?
This study is testing a new drug called BBO-11818 in people with advanced solid tumors. Researchers want to find the safest and most effective dose when the drug is used alone or combined with standard cancer treatments. They will also study its benefits, risks, and side effects in people with cancers that have specific KRAS mutations.
Detalles del Estudio
